The Prioritization of Eleven-Nineteen-Leukemia Inhibitors as Potential Drug Candidates to Treat Acute Myeloid Leukemia
X. S. Guo, P.-H. C. Chen, S. Xu, W. R. Liu
This study identifies compound 13 as a potent ENL inhibitor with favorable pharmacokinetic properties for treating AML with MLL-fusion mutations.